PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

SYGNATURE DISCOVERY COMPLETES MAJOR ENHANCEMENT OF HIGH-THROUGHPUT CHEMISTRY FACILITIES FOLLOWING £1 MILLION INVESTMENT

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment.

In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority. Sygnature’s enhanced high-throughput chemistry (HTC) platform has now doubled its synthesis and purification capacity—delivering twice the output in the same timeframe. This upgrade empowers customers with faster access to high-quality compounds, enabling swifter decision-making and driving progress towards the clinic.

HTC platforms leverage automated systems to efficiently synthesize and purify large volumes of compounds. When integrated with Sygnature’s in-house high-throughput screening (HTS) platform—which rapidly evaluates compound libraries against biological targets—these technologies can accelerate the identification of promising drug candidates.

A cornerstone of the investment is the integration of supercritical fluid chromatography (SFC) into Sygnature’s HTC platform. While SFC is becoming more prevalent, few HTC platforms use SFC for purification. Sygnature now offers both reverse-phase and SFC purification options, providing unparalleled flexibility and optimal purification conditions. Despite SFC systems requiring complex infrastructure and expertise, Sygnature remains focused on delivering best-in-class solutions.  

The upgraded facilities will be fully operational from August and mark a significant milestone in Sygnature’s ongoing growth strategy. 

Geraint Jones, Director of Chemistry at Sygnature Discovery, commented: “Our successful track record over the past 20 years on client projects demonstrates our ability to validate robust syntheses and utilize automated processes to deliver high-quality science quickly and efficiently.” 

“This investment in our capabilities further enhances the value for our customers and reinforces our commitment to delivering cutting-edge services. Our customers want to partner with a CRO that will help them hit their milestones. This expansion proves we are that partner. We have the facilities, flexibility, and scientific excellence to deliver.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026